Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.51 is 454% below its 4-year average of -0.27, near the low end of its 4-year range (-1.51–0.00).
239.33% below its 12-month average of -0.45.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -1.39.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 12 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.51
EARNINGS PER SHARE (EPS) AVG TTM
-0.45
EARNINGS PER SHARE (EPS) AVG 3Y
-0.34
EARNINGS PER SHARE (EPS) AVG 5Y
N/A
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-239.33%
CURRENT VS 3Y AVG
-344.51%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Telomir Pharmaceuticals, Inc. Common Stock
Market Cap
$82.53M
Earnings Per Share (EPS)
-1.51
TTM Avg
-0.45
3Y Avg
-0.34
5Y Avg
N/A
Market Cap
$82.47M
Earnings Per Share (EPS)
-0.60
TTM Avg
-0.82
3Y Avg
-0.86
5Y Avg
-0.88
Market Cap
$82.59M
Earnings Per Share (EPS)
-16.89
TTM Avg
-9.93
3Y Avg
-18.45
5Y Avg
-23.93
Market Cap
$81.22M
Earnings Per Share (EPS)
-0.22
TTM Avg
-0.23
3Y Avg
-0.23
5Y Avg
-0.24
Market Cap
$81.20M
Earnings Per Share (EPS)
-0.57
TTM Avg
-1.79
3Y Avg
-1.21
5Y Avg
-1.06
Market Cap
$84.13M
Earnings Per Share (EPS)
-0.19
TTM Avg
-0.58
3Y Avg
-0.69
5Y Avg
-0.67
Market Cap
$80.30M
Earnings Per Share (EPS)
-0.51
TTM Avg
-0.76
3Y Avg
-0.68
5Y Avg
-1.48
Market Cap
$79.61M
Earnings Per Share (EPS)
-1.88
TTM Avg
-2.06
3Y Avg
-2.07
5Y Avg
-1.66
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | $82.53M | -1.51 | -0.45 | -0.34 | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $82.47M | -0.60 | -0.82 | -0.86 | -0.88 |
| ProMIS Neurosciences, Inc. (PMN)vs › | $82.59M | -16.89 | -9.93 | -18.45 | -23.93 |
| LENSAR Inc (LNSR)vs › | $82.29M | N/A | -2.80 | -2.22 | -2.13 |
| MediciNova, Inc. (MNOV)vs › | $81.22M | -0.22 | -0.23 | -0.23 | -0.24 |
| Nutriband Inc. (NTRB)vs › | $81.20M | -0.57 | -1.79 | -1.21 | -1.06 |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.13M | -0.19 | -0.58 | -0.69 | -0.67 |
| Humacyte, Inc. (HUMA)vs › | $80.30M | -0.51 | -0.76 | -0.68 | -1.48 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | -1.88 | -2.06 | -2.07 | -1.66 |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $85.86M | -1.42 | -1.31 | -1.42 | -1.39 |
Trailing EPS (TTM)
$-1.51
Forward EPS (Est.)
$-0.11
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.33 |
| 2024-12-31 | -0.56 |
| 2023-12-31 | -0.44 |
| 2022-12-31 | -0.03 |
| 2021-12-31 | 0.00 |
